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ABSTRACT: In vitro selection technologies are important
tools for identifying high aﬃnity peptides to proteins of broad
medical and biological interest. However, the technological
advances that have made it possible to generate long lists of
candidate peptides have far outpaced our ability to characterize
the binding properties of individual peptides. Here, we
describe a low cost strategy to rapidly synthesize, purify,
screen, and characterize peptides for high binding aﬃnity.
Peptides are assayed in a 96-well dot blot apparatus using
membranes that enable partitioning of bound and unbound
peptide−protein complexes. We have validated the binding aﬃnity constants produced by this method using known peptide
ligands and applied this process to discover ﬁve new peptides with nanomolar aﬃnity to human α-thrombin. Given the need for
new analytical tools that can accelerate peptide discovery and characterization, we feel that this approach would be useful to a
wide range of technologies that utilize high aﬃnity peptides.
In vitro selection technologies have become indispensibletools for identifying high aﬃnity peptides to proteins of
broad medical and biological interest.1 However, the techno-
logical advances that have made it possible to generate long lists
of candidate peptides have far outpaced our ability to
characterize the binding properties of individual peptides.
This disparity is due, in part, to recent advances in DNA
sequencing technology, which have made it possible to generate
millions of peptide sequences from a single in vitro selection
experiment.2 Other factors that have contributed to the rise in
peptide sequence discovery include the use of bar coded
libraries and liquid handling robots in selection protocols.3
Countering these advances is the slow pace at which
individual peptides are characterized. In many cases, peptides
identiﬁed by in vitro selection are produced by solid-phase
synthesis, puriﬁed by HPLC chromatography, and assayed for
function using analytical techniques, such as surface plasmon
resonance (SPR), that require large amounts of highly pure
peptide or protein. Because this process is both time-
consuming and costly, many researchers have turned to column
binding assays as a way to quickly screen in vitro selected
peptides for high aﬃnity binding.4 Although such assays are
relatively easy to perform and use only small amounts of
peptide, the data produced is not quantitative. These assays also
suﬀer from high background and problems caused by
diﬀerential peptide expression, which can make it diﬃcult to
compare diﬀerent peptides analyzed in side-by-side assays.4b
Even when high aﬃnity peptides are discovered, additional
experiments are needed to obtain quantitative metrics, such as
equilibrium binding aﬃnity constants (Kd) that help describe
the physical properties of the peptide−protein interaction.
Recognizing the limitations of traditional methods, we
sought to develop a new analytical technique to identify high
aﬃnity peptides from enriched pools of in vitro selected
sequences. Our goal was to develop a rapid and inexpensive
method that would make it possible to rank selected peptides
based on their relative binding aﬃnity and, in a second step,
determine the Kd value for the subset of high aﬃnity ligands.
The challenge was to design a system that would require
minimal amounts of peptide and protein, was amenable to
diverse protein classes, and allowed individual assays to be
performed in a parallel format.
We envisioned an overall system in which peptides generated
by cell-free expression would be brought to equilibrium with
their cognate protein, and bound peptide−protein complexes
would be separated from the unbound peptide using a double-
ﬁlter binding assay (Figure 1). We felt that this strategy has a
number of key advantages over existing methods. First, cell-free
peptide synthesis makes it possible to synthesize large numbers
of diﬀerent peptide sequences in a fraction of the time that it
would take to obtain the same constructs by solid-phase
synthesis (hours vs days).5 Second, peptides made by cell-free
synthesis can be engineered to carry a protein aﬃnity tag, which
allows for puriﬁcation by aﬃnity chromatography. Third,
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peptides produced by cell-free synthesis can be labeled with
35S-methionine, a radioisotope that allows for accurate
detection at low concentrations without altering the physical
properties of the peptide. Fourth, ﬁlter-binding assays provide a
useful method for determining Kd values, as binding can be
measured across a range of protein concentrations.6 Last, the
entire process can be performed in parallel, which makes it
possible to simultaneously analyze the binding properties of
many diﬀerent peptides.
To test this strategy, we designed a custom peptide
expression vector that would encode our peptide of interest
followed by a TEV protease cleavage site and the amino acid
sequence for the streptavidin binding peptide (SBP).7,8 We
anticipated that the SBP tag would provide a convenient
positive control for subsequent binding assays, since the SBP−
streptavidin interaction is well-known.9 In our peptide
expression assays, we found that peptides generated in rabbit
reticulocyte lysate could be puriﬁed from the crude lysate by
aﬃnity capture on streptavidin-coated agarose beads. We
developed two elution strategies to recover the peptide from
the beads. The ﬁrst strategy involved eluting the beads with
deionized water, which allowed us to obtain the peptide of
interest as an SBP fusion peptide for control assays with
streptavidin. The second strategy involved eluting the peptide
of interest as a free peptide by incubating the beads with TEV
protease, which separated the peptide of interest from the SBP
portion of the fusion.
While the synthesis and puriﬁcation of SBP-tagged peptides
proceeded without problem, developing a two-membrane
system that could eﬃciently partition bound peptide−protein
complexes from the unbound peptide proved more challenging.
Although ﬁlter-binding assays represent an established method
for studying the binding properties of protein−DNA
interactions7,10 and more recently have been extended to
include protein−XNA complexes,11 such systems have not
been developed for protein−peptide interactions. This is
presumably due to the fact that nitrocellulose has a general
nonspeciﬁc aﬃnity for amino acids, which precludes its ability
to distinguish peptides from proteins.
To identify a suitable membrane pair, we evaluated the
binding properties of several common laboratory membranes
with diﬀerent surface compositions and pore sizes in a dot blot
apparatus. We tested nitrocellulose, PVDF, nylon, and cellulose
membranes with various pore sizes. However, reproducible
results were only observed using a double ﬁlter membrane
setup with a top layer composed of regenerated cellulose and a
bottom layer composed of nylon. Using this membrane
conﬁguration, peptide−protein complexes were retained on
the top cellulose membrane and unbound peptides that passed
through the top membrane were captured on the lower nylon
membrane.
We tested the reproducibility of the cellulose−nylon
membrane system by performing a 96-well dot-blot assay
using SBP and streptavidin to represent a model peptide−
protein complex. In this binding assay, SBP-tagged peptides
labeled with 35S-methionine were equilibrated in phosphate
buﬀered saline (PBS, pH 7) solutions that either lack or contain
streptavidin (50 nM). After 1 h of incubation at 25 °C, the
solutions were loaded into the dot blot apparatus and passed
through cellulose and nylon membranes. The membranes were
removed, dried, and quantiﬁed by phosphorimaging (Figure
2a). Analysis of the individual spots allowed us to quantify the
amount of SBP peptide present on the cellulose and nylon
membranes. We found that 89 ± 2% of the 35S-labeled peptide
was retained on the cellulose membrane when streptavidin was
present in the PBS buﬀer. By contrast, only 19 ± 6% of the 35S-
labeled peptide remained on the cellulose membrane when
streptavidin is absent from the buﬀer. While some variability
was observed across the members, this result suggested to us
that the cellulose−nylon double-ﬁlter system should be
suﬃcient to distinguish the binding properties of diﬀerent
peptides.
For the cellulose−nylon system to function as an accurate
predictor of peptide binding aﬃnity, it was necessary to conﬁrm
that equilibrium was maintained during the ﬁltration step. If
equilibrium were disrupted as the peptide−protein complexes
passed through the membranes, then the observed binding
values would underestimate the true binding aﬃnity of the
Figure 1. General strategy to identify and validate high aﬃnity peptides isolated by in vitro selection. (a) DNA sequences encoding peptides with
ligand binding aﬃnity are inserted into a custom peptide expression vector, expressed in a coupled cell-free transcription−translation system as 35S-
labeled peptides and puriﬁed by aﬃnity chromatography. (b) Peptides are equilibrated in solution with their cognate protein target. (c) Bound and
unbound peptides are separated in a 96-well dot blot apparatus by passing the mixture through a two-membrane system.
Figure 2. Two-membrane double-ﬁltration system for separating
bound and unbound peptide−protein complexes. (a) Analysis of the
streptavidin binding peptide (SBP) on cellulose and nylon membranes
in the absence and presence of streptavidin protein. (b) Equilibrium
dissociation plot measuring the binding interaction of SBP with
streptavidin.
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peptide. To explore this possibility, we measured the binding
aﬃnity constant of the SBP−streptavidin interaction using the
double-ﬁlter assay. SBP-tagged peptides labeled with 35S-
methionine were equilibrated for 1 h in PBS solutions that
contained a range of streptavidin protein concentrations. The
solutions were loaded into the dot blot apparatus and passed
through the cellulose−nylon membranes (Figure 2b). Analysis
of the bound fraction at each SBP concentration yielded a
binding isotherm with a Kd of 2.3 ± 1 nM, which is consistent
with the literature value of 2.4 nM.8 On the basis of this result,
we concluded that equilibrium is maintained for high aﬃnity
peptide−protein complexes.
One of the problems facing those that attempt to identify
high aﬃnity peptides to proteins of medical or biological
interest is the challenge of distinguishing the highest aﬃnity
peptides from a list of in vitro selected peptide sequences. In
many cases, the highest aﬃnity peptides are not the most
abundant sequences or even the sequences that share a
common motif.2 Recognizing this problem, we wondered if our
cellulose−nylon membrane system could be used to identify
and characterize high aﬃnity peptides from a set of in vitro
selected sequences. To explore this possibility, we identiﬁed an
mRNA display selection in which a random library of 1011
diﬀerent mRNA−peptide fusions was used to isolate peptides
that could bind to human α-thrombin.12 The authors reported
45 sequences that remained in the pool after 10 successive
rounds of in vitro selection and ampliﬁcation. Using a column
binding assay, two peptides (T10.39 and T10.11) were
identiﬁed with high aﬃnity to the protein target. Both peptides
were synthesized and tested for binding by surface plasmon
resonance. T10.39 was found to bind human α-thrombin with a
Kd of 166 nM, while T10.11 bound with a Kd of 520 nM.
12
Considering the possibility that some high aﬃnity peptides
may have been overlooked due to the limitations of the original
column binding assay, we decided to test 24 of the 45
sequences in our cellulose-nylon membrane system. The set of
24 peptides were randomly chosen (Figure 3a), inserted into
our custom peptide expression vector, expressed in rabbit
reticulocyte lysate as 35S-labeled peptide fusions, puriﬁed on
streptavidin coated agarose beads, and eluted by TEV protease
cleavage of the fusion peptide. Three of the peptides (T10.35,
T10.46, and T10.57) did not express well and were discarded.
Coincidentally, these three peptides also have high hydrophic
values, indicating that our screen could be an indicator of
peptide solubility. The remaining peptides were each separately
incubated with 250 and 500 nM human α-thrombin for 1 h at
room temperature and analyzed in parallel by passing the
solutions through the cellulose−nylon membrane system.
Control samples lacking thrombin were used to deﬁne the
level of background binding to the membrane and the fraction
of bound peptide was compared to T10.39, a high aﬃnity
thrombin-binding peptide (Figure 3b).
From our ﬁlter-binding assay, we discovered ﬁve previously
uncharacterized sequences (T10.06, T10.13, T10.25, T10.30,
and T10.37) that exhibit at least 25% binding to human α-
thrombin when the protein was poised at a concentration of
250 nM. The remaining sequences showed little or no binding,
indicating that these sequences are all weak aﬃnity ligands. Of
the high aﬃnity peptides, three contain a conserved DPGR
motif that is found in T10.39, while the other two show no
similarity to T10.39 or each other. This could suggest the
peptides bind diﬀerent sites on the surface of human α-
thrombin, with the DPGR containing peptides targeting the
same epitope as T10.39 and the two unique peptides binding
elsewhere on the surface; however, further experiments are
needed to test this hypothesis.
Given the importance of human α-thrombin as a potential
therapeutic target,13 we sought to determine the binding aﬃnity
of the ﬁve novel thrombin-binding peptides. We began by
validating our ﬁlter-binding assay using peptide T10.39, which
was previously characterized and found to bind thrombin with a
Kd of 166 nM.
12 Peptide T10.39 was expressed and puriﬁed as
described above for the SBP peptide. The peptide was then
incubated with a range of thrombin concentrations, and
peptide−protein complexes were separated from the free
peptide by passing the solutions through the cellulose−nylon
membranes. Analysis of the binding isotherm revealed Kd of
170 ± 40 nM, which closely approximates the known literature
value (Figure 4a).12 Moreover, no diﬀerence was observed
when the T10.39 was measured as a free peptide or as an SBP
fusion peptide (data not shown).
Next, we measured the equilibrium binding aﬃnity of the ﬁve
uncharacterized peptides using the same methodology
described above. In each case, the peptides were expressed
and puriﬁed as 35S-labeled free peptide by eluting the peptides
from the beads with TEV protease. The ﬁve peptides were
incubated with a range of thrombin concentrations and their Kd
values were determined by quantifying the amount of 35S-label
on the cellulose and nylon membranes. Peptides T10.25,
T10.30, and T10.6, which share the DPGR motif with T10.39,
Figure 3. Screen of in vitro selected thrombin-binding peptides. (a) A
list of 45 thrombin-binding peptides. Peptides selected for dot blot
analysis (gray).12 (b) Membrane-based screen of 24 thrombin-binding
peptides for aﬃnity to human α-thrombin. Stars indicate peptides with
expression levels below the detection limit for dot blot analysis. High
aﬃnity peptides are numbered in blue. Arbitrary threshold (dashed
blue line).
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have Kd values of 200, 360, and 460 nM, respectively (Figure
4a). By contrast, peptides T10.13 and T10.37, which are unique
with respect to the T10.39 sequence, have Kd values of 160 and
310 nM, respectively (Figure 4b).
To further validate our results, we produced peptides T10.13
and T10.37 by solid-phase synthesis, puriﬁed both sequences
by HPLC chromatography, and conﬁrmed their binding aﬃnity
by microscale thermophoresis (Figure S2 in the Supporting
Information). This technique measures changes in the
hydration shell (due to conformational changes) along a
temperature gradient, which makes it possible to determine Kd
values using minimal amounts of sample.14 We found that
peptides T10.13 and T10.37 bind thrombin with Kd values of
180 and 290 nM, which closely approximates the Kd values
obtained using our double-ﬁlter binding assay.
In addition, we also demonstrated that the high aﬃnity
peptides function in a complex biological medium. In this case,
peptides T10.13 and T10.37 were conjugated to streptavidin-
coated magnetic beads and used to recover recombinant human
α-thrombin that had been doped into HeLa cell lysate. After an
incubation of 1 h at 25 °C, the beads were precipitated, the
supernatant was removed, and the beads were washed with
TBST buﬀer. The supernatant and bead samples were analyzed
by SDS acrylamide gel electrophoresis. Both peptides pulled-
down human α-thrombin from the cell lysate with eﬃciencies
similar to peptide T10.39 and no contamination above the
bead-only control was observed (Figure S3 in the Supporting
Information), demonstrating high aﬃnity and high speciﬁcity
binding.
The past few years have witnessed an explosion in the
demand for high-quality peptides that can be used to support a
growing industry of peptide-based therapeutic and diagnostic
applications. Unlike antibodies, peptides are amenable to
chemical synthesis, generally nonimmunogenic, and their
small size allows them to penetrate further into soft tissue.15,16
These properties, along with improved strategies for increasing
serum stability, warrant new methods to streamline the peptide
discovery process.17 In line with these eﬀorts, we present a
general approach for characterizing the binding properties of in
vitro selected peptides. This approach provides an inexpensive
method to synthesize, purify, screen, and characterize peptides
for high-aﬃnity binding to their cognate protein target. We
validated the method using peptides with known protein-
binding interactions and applied the strategy to identify ﬁve
new peptides that bind to human α-thrombin with nanomolar
aﬃnity and high speciﬁcity.
In summary, we provide a new analytic technique to rapidly
screen and characterize in vitro selected peptides with high
protein binding aﬃnity. We have successfully evaluated
peptides that range in size from 22 to 74 amino acids and
exhibit binding aﬃnity constants of 1−500 nM. While it is
likely that subnanomolar binding aﬃnities could be measured
using this approach, we suspect that weaker interactions may
not be possible due to long transit times through the
membrane. During the course of our study, we noticed that
peptides that do not express well by in vitro translation tend to
have high hydrophobic values, suggesting that peptide recovery
after expression and puriﬁcation could be an indicator of
peptide solubility. This observation could provide a simple way
to determine whether a peptide will be soluble in an aqueous
solution. Relative to more conventional analytical techniques,
like SPR or isothermal titration calorimetry (ITC), the method
presented here allows for rapid screening of multiple peptide
candidates in small sample volumes using cell-free translated
peptides that can be obtained in a cost-eﬀective manner. By
contrast, SPR and ITC generally require large amounts of
puriﬁed peptide and/or protein that can be cost prohibitive
when screening large numbers of peptides. While our approach
is ideal for peptide screening and characterization, high aﬃnity
ligands discovered using this method may require further
characterization in order to obtain a complete kinetic and
thermodynamic proﬁle of the peptide−protein interaction.
Recognizing the advantages of small sample volumes, low cost,
and high throughput, we suggest that this strategy could be
used to accelerate the pace of peptide characterization and help
advance the development of peptide-based aﬃnity reagents.18
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